An Update on MDMX and Dual MDM2/X Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The tumor suppressor protein p53 is crucial for preventing cancer but is often inactivated in tumors.
• In cancers retaining wild-type p53, inactivation occurs via negative regulators like MDM2 and MDMX, which are frequently overexpressed.
• Inhibiting MDM2 and MDMX is a promising therapeutic strategy to restore p53's tumor-suppressive functions.

Purpose of the Study:

• To review recent advancements in developing small molecules and stapled peptides targeting MDMX or both MDM2 and MDMX.
• To highlight therapeutic strategies aimed at reactivating wild-type p53 for cancer treatment.

Main Methods:

• Focus on the discovery and development of novel small molecules and stapled peptides.
• Investigating inhibitors of MDM2 and MDMX, including selective MDMX inhibitors and dual MDM2/MDMX inhibitors.

Main Results:

• Several small molecules targeting MDM2 have progressed to clinical trials.
• MDMX has emerged as a significant therapeutic target for p53 reactivation.
• Dual inhibition of MDM2 and MDMX is considered necessary for complete p53 reactivation.

Conclusions:

• Targeting MDM2 and MDMX with novel small molecules and stapled peptides represents a vital approach in cancer therapy.
• Restoring p53 activity through inhibition of its negative regulators offers a promising avenue for treating various human cancers.